Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2012 3
2013 3
2014 9
2015 8
2016 8
2017 9
2018 6
2019 13
2020 17
2021 20
2022 8
2023 3
2024 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Cascone T, et al. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. N Engl J Med. 2024. PMID: 38749033 Clinical Trial.
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.
Genova C, Marconi S, Chiorino G, Guana F, Ostano P, Santamaria S, Rossi G, Vanni I, Longo L, Tagliamento M, Zullo L, Dal Bello MG, Dellepiane C, Alama A, Rijavec E, Ludovini V, Barletta G, Passiglia F, Metro G, Baglivo S, Chiari R, Rivoltini L, Biello F, Baraibar I, Gil-Bazo I, Novello S, Grossi F, Coco S. Genova C, et al. Among authors: rijavec e. Clin Exp Med. 2024 Aug 6;24(1):182. doi: 10.1007/s10238-024-01427-8. Clin Exp Med. 2024. PMID: 39105937 Free PMC article.
Metabolic disorders and the risk of cholangiocarcinoma.
Ghidini M, Ramai D, Facciorusso A, Singh J, Tai W, Rijavec E, Galassi B, Grossi F, Indini A. Ghidini M, et al. Among authors: rijavec e. Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):999-1007. doi: 10.1080/17474124.2021.1946393. Epub 2021 Aug 21. Expert Rev Gastroenterol Hepatol. 2021. PMID: 34423721 Review.
Ramucirumab: preclinical research and clinical development.
Aprile G, Rijavec E, Fontanella C, Rihawi K, Grossi F. Aprile G, et al. Among authors: rijavec e. Onco Targets Ther. 2014 Oct 29;7:1997-2006. doi: 10.2147/OTT.S61132. eCollection 2014. Onco Targets Ther. 2014. PMID: 25378934 Free PMC article. Review.
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study.
Bironzo P, Morabito A, Silipigni S, Adamo V, Capelletto E, Rossi S, Tiseo M, Montrone M, Facilissimo I, Romano G, Masini LC, Ceresoli GL, Gridelli C, Lugini A, Pilotto S, Tagliaferri P, Bria E, Cortinovis D, Rijavec E, Borghetti P, Brighenti M, Carta AM, Ciuffreda L, Giusti R, Macerelli M, Verderame F, Zanelli F, Berardi R, Gregorc V, Sergi C, Vattemi E, Ferrara R, Piovano PL, Livi L, Borra G, Gori S, Aieta M, Bertolini A, Cecere FL, Pasello G, Rocco D, Certo GL, Marrone L, Simoni L, Roncari B, Novello S, Ramella S; BE-PACIFIC Study Group. Bironzo P, et al. Among authors: rijavec e. Cancer Treat Res Commun. 2026;47:101143. doi: 10.1016/j.ctarc.2026.101143. Epub 2026 Feb 16. Cancer Treat Res Commun. 2026. PMID: 41747469 Free article.
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, Grossi F, Genova C. Tagliamento M, et al. Among authors: rijavec e. Expert Opin Biol Ther. 2018 Jul;18(7):829-835. doi: 10.1080/14712598.2018.1492539. Epub 2018 Jul 4. Expert Opin Biol Ther. 2018. PMID: 29936901 Review.
Immune checkpoint inhibitor therapy for hepatocellular carcinoma.
Ramai D, Shapiro A, Facciorusso A, Bareggi C, Gambini D, Rijavec E, Tomasello G, Galassi B, Ghidini M. Ramai D, et al. Among authors: rijavec e. Ann Gastroenterol. 2022 Nov-Dec;35(6):568-576. doi: 10.20524/aog.2022.0746. Epub 2022 Oct 3. Ann Gastroenterol. 2022. PMID: 36406972 Free PMC article. Review.
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S, Grossi F. Tagliamento M, et al. Among authors: rijavec e. Expert Opin Pharmacother. 2018 Dec;19(18):2055-2062. doi: 10.1080/14656566.2018.1540591. Epub 2018 Nov 3. Expert Opin Pharmacother. 2018. PMID: 30392436 Review.
101 results